# Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to TNF-α Antagonist Therapy

> **NCT00603525** · PHASE3 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 169 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** Ofatumumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00603525
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-01
- **Primary completion:** 2011-03
- **Final completion:** 2013-07
- **Target enrollment:** 169 (ACTUAL)
- **Why stopped:** Ofatumumab IV trials in RA were prematurely terminated because GSK refocused clinical development of autoimmune indications on the subcutaneous delivery.
- **Last updated:** 2014-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00603525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00603525, "Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to TNF-α Antagonist Therapy". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00603525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*